GILD:NSD-Gilead Sciences, Inc (USD)

COMMON STOCK | Drug Manufacturers—General | NSD

Last Closing Price

USD 62.25

Change

0.00 (0.00)%

Market Cap

USD 78.04B

Volume

7.14M

Average Target Price

USD 81.93 (+31.62%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AMGN Amgen Inc

N/A

USD142.80B 20.25 13.34
SNY Sanofi

N/A

USD127.60B 9.72 7.75
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

N/A

USD43.26B 7.93 5.70
HZNP Horizon Therapeutics Public Li..

N/A

USD17.24B 28.75 52.14
GRFS Grifols, S.A

N/A

USD16.17B 17.05 17.15
GWPH GW Pharmaceuticals plc

N/A

USD3.26B 91.14 84.16

ETFs Containing GILD

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.49B
HDLG:LSE Invesco S&P 500 High Divi.. 0.00 % 0.30 %

N/A

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

N/A

USD0.19B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

USD0.15B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

N/A

N/A
UXM-B:CA CI First Asset Morningsta.. 0.00 % 0.60 %

N/A

N/A
ZDY-U:CA BMO US Dividend ETF (USD) 0.00 % 0.30 %

N/A

N/A
FHI-B:CA CI First Asset Health Car.. 0.00 % 0.65 %

N/A

N/A
SPBO SPDR Portfolio Corporate .. 0.00 % 0.06 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.07B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.26B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.26B
HDLV:LSE Invesco S&P 500 High Divi.. 0.00 % 0.30 %

N/A

N/A
IVFVC Ivy Focused Value NextSha.. 0.00 % 0.78 %

N/A

USD8.39M
IUVD:LSE iShares Edge MSCI USA Val.. 0.00 % 0.20 %

N/A

USD1.03B
IUVF:LSE iShares Edge MSCI USA Val.. 0.00 % 0.20 %

N/A

USD1.03B
IUVL:LSE iShares Edge MSCI USA Val.. 0.00 % 0.20 %

N/A

USD1.15B
MOAT:LSE VanEck Vectors Morningsta.. 0.00 % 0.49 %

N/A

USD0.22B
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

N/A
HDLV:PA Invesco S&P 500 High Divi.. 0.00 % 0.30 %

N/A

N/A
HDLV:F Invesco S&P 500 High Divi.. 0.00 % 0.30 %

N/A

N/A
QDVI:F iShares Edge MSCI USA Val.. 0.00 % 0.20 %

N/A

USD1.03B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
HDLV:XETRA Invesco S&P 500 High Divi.. 0.00 % 0.30 %

N/A

N/A
FHI:CA CI First Asset Health Car.. 0.00 % 0.65 %

N/A

USD0.20B
AIEQ AI Powered Equity ETF 0.00 % 0.87 %

N/A

USD0.09B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.21B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

USD0.26B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD0.01B
BSCK Invesco BulletShares 2020.. 0.00 % 0.10 %

N/A

USD1.55B
BSCQ Invesco BulletShares 2026.. 0.00 % 0.10 %

N/A

USD0.29B
CBND SPDR Bloomberg Barclays C.. 0.00 % 0.06 %

N/A

USD0.08B
DTN WisdomTree U.S. Dividend .. 0.00 % 0.38 %

N/A

USD0.53B
DVP Roundhill Acquirers Deep .. 0.00 % 0.59 %

N/A

USD0.02B
ESGW Columbia Sustainable Glob.. 0.00 % 0.40 %

N/A

USD0.01B
FDRR Fidelity Dividend ETF for.. 0.00 % 0.29 %

N/A

USD0.30B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

N/A

USD9.52B
IBCD iShares iBonds Mar 2020 T.. 0.00 % 0.10 %

N/A

USD0.08B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD0.36B
ZVU:CA BMO MSCI USA Value Index .. 0.00 % 0.30 %

N/A

USD0.03B
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

N/A

USD3.76M
SCIU Global X Scientific Beta .. 0.00 % 0.19 %

N/A

USD0.02B
SPHD Invesco S&P 500 High Divi.. 0.00 % 0.30 %

N/A

USD2.45B
SPYD SPDR Portfolio S&P 50.. 0.00 % 0.07 %

N/A

USD1.92B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
UXM:CA CI First Asset Morningsta.. 0.00 % 0.60 %

N/A

USD0.03B
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.45 %

N/A

USD0.27B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.45 %

N/A

USD0.06B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZDY:CA BMO US Dividend ETF (CAD) 0.00 % 0.30 %

N/A

USD1.33B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

N/A

USD0.33B
QDVI:XETRA iShares Edge MSCI USA Val.. 0.00 % 0.20 %

N/A

USD1.03B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.20% 43% F 55% F
Dividend Return 3.14% 67% D+ 80% B-
Total Return -1.06% 57% F 57% F
Trailing 12 Months  
Capital Gain -1.03% 43% F 55% F
Dividend Return 4.24% 100% A+ 79% C+
Total Return 3.21% 43% F 58% F
Trailing 5 Years  
Capital Gain -34.34% 14% F 29% F
Dividend Return 11.80% 50% F 43% F
Total Return -22.53% 14% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -5.35% N/A N/A 25% F
Dividend Return 2.99% N/A N/A 72% C-
Total Return -2.37% N/A N/A 28% F
Risk Return Profile  
Volatility (Standard Deviation) 14.64% N/A N/A 81% B-
Risk Adjusted Return -16.17% N/A N/A 26% F
Market Capitalization 78.04B 71% C- 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.91 57% F 47% F
Price/Book Ratio 4.33 43% F 30% F
Price / Cash Flow Ratio 8.54 71% C- 32% F
EV/EBITDA 46.27 43% F 14% F
Management Effectiveness  
Return on Equity -1.40% 29% F 51% F
Return on Invested Capital 9.37% 57% F 78% C+
Return on Assets 4.37% 71% C- 81% B-
Debt to Equity Ratio 98.09% 43% F 24% F
Technical Ratios  
Short Ratio 1.67 71% C- 66% D
Short Percent 1.29% 75% C 74% C
Beta 0.58 57% F 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector